Across TCGA pan-cancer cohorts, SERPINI1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SERPINI1 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SERPINI1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SERPINI1 expression acts as an unfavorable survival marker.
LIHC, SKCM, and LUAD are the cancer types where SERPINI1 Mutation most reproducibly stratifies survival.